NovoCure's FDA-Approved Head Flexible Electrode Arrays Revolutionize Glioblastoma Treatment

### Advancements in Glioblastoma Treatment: Novocure's Innovative Head Flexible Electrode Arrays

Novocure, a pioneering company in the field of oncology, recently receives FDA approval for its new Head Flexible Electrode (HFE) transducer arrays intended for use with the Optune Gio® device. This device is specifically designed to treat adult patients suffering from glioblastoma multiforme (GBM), an aggressive form of brain cancer. The Optune Gio device leverages Tumor Treating Fields (TTFields), a novel therapy that uses non-invasive arrays to deliver electric fields targeting rapidly dividing cancer cells. The newly designed HFE arrays, constructed from a flexible polymer, are a significant improvement over the previous ceramic disc versions, being one-third lighter and 50% thinner. This innovation not only enhances patient comfort but also reflects Novocure's commitment to prioritizing the needs of patients battling challenging cancers.

The introduction of the HFE arrays marks a pivotal advancement in Novocure's treatment offerings. Mukund Paravasthu, the Chief Operating Officer of Novocure, emphasizes that this innovation is crucial for improving patient outcomes. The company plans to implement a controlled transition for existing Optune Gio users to the HFE arrays by the first half of 2025. This approach ensures that patients can benefit from the enhanced design of the device while maintaining continuity in their treatment regimen. The Optune Gio device remains a critical option for newly diagnosed GBM patients aged 22 and older, as it is utilized alongside the chemotherapy agent temozolomide (TMZ) after surgical intervention. For recurrent cases, it serves as a standalone treatment when other therapies fail, underscoring the versatility of this innovative technology.

Additionally, Novocure's commitment to advancing glioblastoma treatment is further demonstrated through its participation in the upcoming 29th Annual Scientific Meeting and Education Day of the Society for Neuro-Oncology (SNO). Scheduled for November 21-24 in Houston, Texas, Novocure will present new research findings related to TTFields therapy, including the efficacy of the new HFE arrays. Key presentations will highlight the impact of TTFields on glioblastoma, with over 20 independent studies reinforcing the potential of this therapy to improve patient outcomes when combined with existing cancer treatments. The symposium titled "From Evidence to Practice: Impact of TTFields Therapy on Patient Outcomes" reflects Novocure's dedication to translating scientific evidence into practical applications for patients.

In summary, Novocure's recent FDA approval of the Head Flexible Electrode arrays for the Optune Gio device signifies a critical milestone in the fight against glioblastoma. The company's ongoing commitment to innovation and research positions it as a leader in oncology, offering hope to patients battling one of the most aggressive forms of cancer.